Purpose: This retrospective longitudinal study aims to compare the longer-term cognitive and behavioral side effects of adjunctive antiepileptic treatment with perampanel (PER) and lacosamide (LCM), two third generation antiepileptic drugs with suggested favorable cognitive profiles. The two drugs were monitored according to a previously established routine diagnostic protocol (Helmstaedter et al. E&B 2013;26:182-7) which facilitates the retrospective comparison of antiepileptic drug tolerability in a naturalistic outpatient setting. Methods: Records from 94 patients were evaluated who underwent neuropsychological assessment before and under adjunctive treatment with either PER (n = 57) or LCM (n = 37). Cognition was assessed using the EpiTrack screening for executive functions and a VLMT short form for verbal memory. Subjective assessments included a German QOLIE-10 adaptation (quality of life) and an extended Adverse Events Profile (AEP). The median follow-up interval was 36 weeks. Results: Multivariate repeated measures statistics revealed a non-significant trend towards an interaction effect "time À treatment arm" on both executive function and memory. When analyzed separately executive functions and memory scores significantly improved under LCM (t = À2.76 p < 0.01 and t = À2.44 p < 0.05 respectively). Subjectively, PER was associated with improvements in 2/18 physiological domains and in the LCM group 1/9 cognitive domains deteriorated. Seizure freedom was achieved for five patients treated with LCM (14%) and 15 treated with PER (26%, x 2 = 2.2, n.s.). Conclusion: In a naturalistic outpatient setting, chronic adjunctive treatment with PER and LCM did not negatively affect cognition and LCM may even improve cognition. Neither drug increased self-reported irritability or aggression. This suggests favorable longer-term tolerability.
Introduction
About 60% of patients with epilepsy become seizure-free with the first or second antiepileptic drug (AED). Adding more AED only marginally increases the seizure free rate [1] . In order to improve treatment for the remaining patients, development of AED with new mechanisms of action is crucial. Additionally, newer AED generally exhibit fewer cognitive and behavioral side effects [2] . These belong to the least tolerated side effects [3] , they can affect drug retention more than lack of seizure control [4] , and they have been shown to be associated with lower subjective quality of life [5] . Some new AED have even been associated with cognitive improvement [6] . The current study aims to compare cognitive side effects of treatment with two newer AED, perampanel (PER) and lacosamide (LCM) in a naturalistic outpatient setting.
PER is a selective, noncompetitive antagonist to a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, a class of ionotropic glutamate receptors [7] . It was licensed as adjunctive medication for partial-onset and generalized seizures in 2012 and is in the evaluation process for monotherapy in Europe [8] . In Germany, PER was withdrawn from the market in 2013 following the implementation of a law to reduce healthcare costs (AMNOG, Gesetz zur Neuordnung des Arzneimittelmarktes). After pricing disputes have been settled, it has been reintroduced to the German market in 2018.
The efficacy of PER in the treatment of partial-onset seizures has been demonstrated in three randomized controlled studies with a total of 1331 patients [7, 9, 10] . In these three trials, the most frequently reported adverse events were generally mild or moderate such as dizziness or somnolence.
Cognitive effects of PER have been investigated by Meador and colleagues [11] in adolescents with epilepsy. This study provided no evidence for a change in the global cognitive score but suggested possible benefits and disadvantages in individual scores, though effect sizes were small. Data from the extension phase also did not show an effect of long-term adjunctive treatment with PER on the global cognitive score [12] . Psychiatric adverse events seemingly arose more frequently [13] . A dose-dependent increase in hostility and aggression became apparent in the randomized controlled trials [14] . Recently the FDA demanded a boxed warning for "serious psychiatric and behavioral adverse reactions" including homicidal ideation and threats in the US prescribing information [15] . In one retrospective analysis of clinical experience with PER, 10% of the participants discontinued treatment because of behavioral reactions including suicidal ideation and aggressive behavior [16] , while in another, PER showed similar clinical efficacy and a higher retention rate than levetiracetam (LEV) [17] .
Lacosamide (LCM) is believed to take effect by increasing the number of voltage-gated sodium channels (VGSC) in the cell membrane that enter into the slow inactivated state. This does not influence normal synaptic transmission (fast inactivation of VGSC) but reduces the overall availability of VGSC. It may therefore selectively inhibit pathological activity [18] . LCM was approved in 2008 as adjunctive and monotherapy for patients with partialonset seizures with or without secondary generalization. Three placebo-controlled trials with a total of 1308 patients demonstrated the efficacy of LCM in reducing seizures as well as its tolerability [19] [20] [21] .
LCM has been associated with signs of vestibulocerebellar dysfunction such as dizziness, vertigo, and ataxia which emerge with increased dosage [22] . Up to now there is little evidence for any cognitive side-effects, though a pooled analysis of adverse events from randomized controlled trials suggests a dosedependent increase of self-reported memory problems [23] . When objective measures are employed, LCM does not seem to induce negative effects on cognition in patients with epilepsy [24] . In a randomized, double-blind, two-period crossover study Meador and colleagues [25] found that healthy adults experienced fewer cognitive side effects when treated with LCM compared to carbamazepine (CBZ). LCM seems to exhibit a favorable cognitive profile similar to lamotrigine (LTG) and LEV. Similarly, Liguori et al. found that executive functions as assessed by the EpiTrack actually improve after introduction of LCM as compared to CBZ in a series of 16 cases [26] .
When directly comparing PER and LCM, clinical outcomes showed relatively high responder rates in patients with refractory epilepsies [27] . The present study aimed to compare the longerterm cognitive and behavioral effects of adjunctive treatment with PER or LCM. According to the literature, we hypothesized no particular cognitive side effects. In addition, following recent reports on negative behavioral effects of PER, the behavioral outcomes were of special interest.
The study followed a retrospective, observational, controlled protocol which had been applied before when comparing LCM, topiramate, and LTG in a natural outpatient setting [24] . Following the experience with this and previous studies [6, 28] , an ongoing routine diagnostic screening protocol has been established at the epilepsy center in Bonn which facilitates monitoring of the efficacy as well as objective and subjective side effects on cognition and behavior of the longer-term use of all new AED [29] .
Method

Study design and participants
This retrospective longitudinal study is based on records from patients who were tested before and during the longer-term treatment with PER or LCM at the epilepsy center in Bonn. Here, physicians can make use of a neuropsychological service to monitor cognition and behavior along with pharmacological treatment changes [29] . Since examinations are scheduled by the physician according to individual treatment concerns, followup intervals can be relatively long. Additionally, some patients decide against trying new medication or discontinue it after consulting in-house or local physicians, some did not return to the clinic within the observation interval and in some cases a followup examination was impossible because of logistic difficulties. A summary of the drop-out rates can be found in Supplementary Table 1.
Neuropsychological assessment
The standardized diagnostic screening package used has been described in more detail in a previous publication [24] . It contains measures of attention and executive functioning, verbal memory, quality of life and subjective side effects.
The EpiTrack [30] is a screening tool for executive function which is especially sensitive to drug effects and therefore uniquely appropriate for monitoring ongoing treatment [31] . It consists of six subtests that contribute to an age-corrected total score. Patients can achieve a maximum score of 49 (after age-correction). A total score of 29-31 points indicates mild impairment and the cutoff for significant impairment is 28 points. Significant change is indicated by a gain of >3 points or loss of >2 points.
Verbal memory was examined using a shortened version of the Verbaler Lern-und Merkfähigkeitstest (VLMT) [32] , the German adaptation of the Rey Auditory Verbal Learning Test (RAVLT). According to normative data of 383 healthy subjects, scores for learning, memory and loss over time were converted into a total score and corrected for age [24] . After age correction, total memory scores from 14 to 18 were rated as normal, scores greater than 18 as above average, scores from 11 to 13 as mild impairment, and scores of 10 as significant impairment. Changes were considered significant when there was a gain of >3 points or loss of >5 points.
Self-perceived side effects of AED were assessed by an extended Adverse Event Profile (AEP). The self-rating scale considers nine cognitive, five behavioral and 18 physiological symptoms [24] . Patients were asked to rate the presence and strength of impairments which they explicitly attribute to drug treatment on a four-tiered scale ranging from not at all (0) to strong (3).
Quality of life (QoL) was assessed via the German adaptation of the Quality of Life in Epilepsy (QOLIE)-10 questionnaire [33] . In the German version, 13 items covering epilepsy-and treatment related issues are rated from 1 to 5 with greater values reflecting worse QoL. As in previous publications, total scores exceeding half of the possible maximum were arbitrarily defined as indicating impairment (cutoff: >32). Change in QoL was rated as significant when a patient's baseline score changed by more than eleven points.
Statistical analyses
Baseline characteristics of the study groups were compared by T-tests and frequency statistics (x 2 ) of categorical data. Changes in objective test performance and QoL were evaluated by repeated measures analysis of covariance (MANCOVA) with time as withinand treatment arm as between-subjects factor. Performance changes were controlled by considering the number of AED at follow-up as a covariate. Since the QOLIE-10 questionnaire is not standardized in regard to age, age was an additional covariate in the analysis of subjective quality of life. Individual level analyses compared the percentage of patients with impairments at baseline and of patients with significant individual changes. Changes in subjective ratings of treatment-related side effects were analyzed within each treatment arm via t-tests for dependent measures. Group differences were determined by comparing the number of ratings per domain (cognitive, behavioral, and physiological) which changed significantly.
Results
Patient demographics and baseline characteristics
One hundred patients of the outpatient department who started adjunctive treatment with LCM (n = 42) or PER (n = 58) between 09/2008 and 02/2015 underwent standardized cognitive assessment before and during treatment. Six patients had to be excluded due to missing data, reducing the total sample size to 94. Demographic and baseline characteristics are summarized in Table 1 . Patients were diagnosed with focal symptomatic (n = 68) or cryptogenic epilepsy (n = 26), no idiopathic cases were included. At baseline the patient groups did not differ in regard to drug load (number of concurrent AEDs and total Defined Daily Dose). In both treatment arms, the number of AEDs and the total Defined Daily Dose (DDD) were higher at follow up compared to baseline, and at follow up the patients in the PER treatment arm had more AED than in the LCM arm. The number of AED at follow-up was therefore taken into account as covariate in the analyses on cognition.
Seizure freedom was achieved in 15 (26%) of the patients treated with PER and in five (14%) of the patients treated with LCM. Two patients in the LCM treatment arm were seizure free at baseline and relapsed while one patient with PER was seizure free at baseline and stayed that way.
Due to the naturalistic setting, the treatment groups were not assigned randomly and patients were typically on different, sometimes changing, concomitant drugs (see Table 2 ). In the PER treatment arm, 14 patients were also on LCM at baseline and 11 at follow-up while in the LCM treatment arm, one patient was treated with PER at both baseline and follow up. Therefore, the analysis focuses on the effects of adjunctive introduction of LCM or PER on cognition in a longitudinal study design. LEV and LTG were the most frequently used concomitant AED. Eslicarbazepine acetate (ESL) was used more often in the PER treatment arm than in the LCM treatment arm at baseline, no other group differences were detected.
At baseline, impaired executive functions were seen in more than half of all patients (58 and 54% in the PER and LCM group respectively), memory was impaired even more often (60 and 68% respectively). Quality of life was reduced in 64 and 77% of patients respectively. No significant differences between treatment arms were observed (see Table 3 ).
Objective cognitive outcome
In a repeated measures MANCOVA with time as within-subject factor and treatment arm as between-subject factor and statistical control for number of AED at follow-up, the interaction effect of "treatment arm X test time" on EpiTrack performance showed a trend towards significance (F = 3.56, p = .063, h 2 = .04; Fig. 1A) . No other main effect (ME) or interaction effect (IE) approached statistical significance (ME time: F = 0.1, n.s.; IE time X number of AED at follow-up: F = 0.04, n.s.). Table 3 displays the mean performances and standard deviations at T1 and T2 with statistics comparing the performances across the treatment arms at baseline (ANOVA) as well as within-group comparisons across test-times (T-tests for dependent measures). The trend towards interaction seems to be driven by a slight but significant improvement of EpiTrack scores in the LCM treatment arm (T = À2.76, p = .009, Cohen's d = .445) that does not occur in the PER treatment arm.
A similar but less distinct non-significant trend is seen in the analysis of verbal memory performance: The interaction term time X treatment arm with F = 2.90 (p= .092, h 2 = .03; Fig. 1B) reflects the fact that LCM treatment is associated with a significant increase in memory performance (T = À2.44, p = .02, Cohen's d = .376) while PER treatment is not. No other effects were observed (ME time: F = 0.24, n.s.; IE time X number of AED at followup: F = 0.51, n.s.).
Analyses of significant individual changes as a trend reflect the findings on a group level. More patients with LCM (27%) showed a significant improvement with regard to EpiTrack performance compared to the patients with PER (12%), while 11% of the LCM group deteriorated compared to 14% of the PER group. However, this at first glance differential finding did not reach statistical significance (see Table 3 ). Similarly, the individual changes in verbal memory function did not differ between treatment arms: Memory improved significantly in 5% of the PER group compared to 14% of the LCM group and deteriorated in one patient (2%) treated with PER but no patient treated with LCM.
Outcome in subjective measures
Quality of life
As the normalization of the QOLIE-10 does not include an age correction, the repeated measures analysis for QoL considered chronological age as additional covariate. No significant main or interaction effect was detected (ME time: F = 2.45, p = .122; IE timetreatment arm: F = 0.24, p = .628; IE time -number of AED at followup: F = 0.18, p = .676; IE time -age: F = 2.92, p = .091).
QoL ratings improved in 7% of all patients and deteriorated in 11%. No significant inter-group differences were detected.
Self-perceived side effects
Scales on self-perceived side effects concerning cognition, behavior and physiology were analyzed separately for each treatment arm. Patients treated with LCM reported similar levels of adverse events at T1 and T2 apart from problems with recent memory, which increased (T = 2.37, p = .024). Those in the PER treatment arm reported improvement in two physiological domains, shaking hands (T = 2.33, p = .024) and nausea (T = 2.63, p = .011).
Contrary to hypotheses, treatment with PER did not lead to an increase in self-perceived aggression (T = À.48, n.s.), irritability (T = À1.03, n.s.) or agitation (T = .85, n.s.).
Discussion
PER and LCM are both newer AED that have only recently been approved for treatment of epilepsy in Europe. In Germany, PER has been withdrawn from the market in 2013, but it has been reintroduced in 2018. In this study, a relatively large sample of 94 patients made it possible to compare both AED's effects on cognition in a retrospective, longitudinal study design using a naturalistic outpatient setting. To our knowledge, it is the first study directly comparing these two substances with a focus on their neuropsychological (side) effects. At baseline, the two groups did not differ in distribution of sex, age, education, duration of epilepsy, drug load or seizure frequency. Both drugs appeared to have similar efficacy in reducing seizure frequency. Seizure free rates were only numerically higher in patients treated with PER. Drug load turned out to be higher in the PER treatment arm.
Since up to now no cognitive side effects have been described for PER or LCM, we expected no negative change. These assumptions were largely confirmed by the objective screening of executive functions using the EpiTrack and verbal memory via a short version of the VLMT. Even though the total number of AED increased between baseline and follow-up, neither group showed cognitive deficits after introduction of adjunctive PER or LCM. Witt and colleagues [34] showed that while the number of AED is negatively associated with cognitive performance, LTG and LEV do not put additional strain on cognition so that higher drug loads can be tolerated. Quite possibly, PER and LCM can also be counted among the more cognitively "benign" AED.
As for differences between the two treatment arms, LCM even seemed to slightly improve executive and memory functions while these functions remained stable under adjunctive treatment with PER. Calculated separately for the groups the changes were significant for LCM. When comparing the groups, the trend towards interaction did not get significant. Whether LCM has a genuine stimulating effect as has been discussed in conjunction with LEV or LTG cannot be inferred from the present data [6, 26, 34] . Withdrawal of other drugs with less favorable cognitive profiles may well have caused a release effect, improving the overall performance. Even though the group difference in drug load at follow-up was controlled for in the analyses, a differential release effect is possible.
In regard to subjective measures it is essential to note that PER has been associated with increased hostility and aggression compared to placebo in the three phase III studies [14] and in clinical practice [16] . In fact the PER labeling includes a warning for psychiatric symptoms such as aggression, hostility, irritability, anger and homicidal ideation [15] . In this study, no increase of selfreported irritability or aggression was detected under the chronic intake of PER. Interestingly, out of 27 patients that went through pre-screening and discontinued PER before follow-up, eight (29.6%) discharge letters explicitly noted increased irritability or aggression as side effects (compared to 4.9% of patients with LCM). Thus, when considering the whole sample, an estimated 6% of patients discontinued PER because of psychiatric side effects, which is comparable to earlier studies [16] . This figure may be a conservative estimate as it is quite possible that some occurrences of irritability were not noted in the discharge letter. Regardless, it follows that those patients that keep on using PER long-term tolerate it without noticing changes in their behavior. As many patients arrive at the clinic alone or accompanied by different people, a reliable assessment of possible behavioral changes that patients themselves were not aware of could not be established.
Patients in the LCM treatment arm reported subjective deterioration of recent memory function similar to data from the randomized controlled trials [23] even though objectively assessed memory function tended to improve over time in the LCM group. This once more confirms the loose connection of subjective and objective assessment of memory function which is overshadowed by mood, the degree of memory impairment, and lay concepts of episodic memory [35] [36] [37] [38] .
The naturalistic outpatient setting is both strength and shortcoming of the study design. As the study was conducted in a tertiary care facility specialized in epilepsy, many patients had highly refractory epilepsies as indicated by the number of concomitant drugs and failure to achieve seizure control despite long duration of epilepsy treatment. Patients were seen at baseline when treatment with PER or LCM was planned, but whether retesting took place depended on a number of factors: We lost those cases where the drug was never introduced or discontinued, where the patient was not re-admitted (within the timeframe of the study), and where testing could not take place because of logistic difficulties. There is no easy way to control these factors and consequently, the patient selection is not representative of all patients who were put on the respective drugs. Additionally, since the choice of drug regimen was based entirely on the in-house or external physicians' decisions, a randomized controlled approach was impossible.
At the same time, the study design shows a realistic picture of the actual clinical treatment situation and can be applied to any new drug which enters the market. In this study, the data supports previous findings that those patients who are treated chronically with PER or LCM do not suffer from additional cognitive side effects [12, 24] . LCM may even be beneficial for cognition. We also did not see any behavioral side effects of PER or LCM in longer-term use. Since previous reports have raised awareness of increased aggression and irritability with PER use, presumably treatment was discontinued quickly if behavioral changes were noted after introduction of PER. Those patients who retained PER did not suffer from increased aggression in the present study which seems to suggest that behavioral changes may only appear in a subsample of patients. An increased awareness of these kinds of side effects may be seen as effective precaution. Definite conclusions cannot be drawn due to the limitations of the study design. In keeping with previous findings, both LCM and PER showed satisfying efficacy in mostly drug-resistant epilepsies. Seizure free rates were numerically higher in the PER treatment arm. All in all, findings indicate that both LCM and PER are favorable treatment options in clinical practice.
In conclusion, the data confirm the benign cognitive effects of the adjunctive longer-term treatment with PER and LCM in a naturalistic setting. LCM may even have some positive effect although as already mentioned above the present study design is ill-suited to examine the causes of this trend. Behavioral effects may be negligible in chronic use.
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